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Investigation and Synthesis of Novel Aromatic Azo Inhibitors of LMW-PTP Isoform B 
Abstract 
 The goal of this investigation was to synthesize novel aromatic azo inhibitors based on an 
aromatic azo inhibitor discovered from in silico screening against Low Molecular Weight Protein 
Tyrosine Phosphatase (LMW-PTP).  These inhibitors were then tested in vitro aginst LMW-PTP 
Isoform B.  The synthesis of the inhibitor of interest was achieved via a Sandmeyer reaction, 
utilizing p-aminobenzoic acid.  The nucleophile used in the synthesis, 3-hydroxy-2-naphthoic 
acid, was linked with p-aminobenzoic acid, and the final product was purified via 
recrystallization.  Characterization techniques included 1H-NMR, 13C-NMR, COSY, and HMQC.  
This newly synthesized product was an analogue to a previously synthesized competitive 
inhibitor, 156563, which had an inhibitor dissociation constant of 33.5µM.  By synthesizing an 
analogue to inhibitor 156563, our group hopes to probe the carboxylic acid chain length as a 
function of inhibition. 
Introduction 
 It is essential that the body regulates signal transduction methods for cellular 
communication.  Some of these signal transduction methods may include paths that control cell 
growth and proliferation, motility and even gene expression.  The body regulates signal 
transduction through post-translational modifications, and one of the key post-translation 
modifications involves phosphorylation—and dephosphorylation—of residues in proteins in a 
process known as reversible post-translational phosphorylation1.  Phosphorylation is the addition 
of a phosphoryl group (PO3-) to a molecule.  An extensive amount of proteins, sugars, lipids, and 
other molecules are often temporarily phosphorylated in order to carry out vital functions2.  
Phosphorylation and dephosphorylation, the opposite of phosphorylation, work hand-in-hand in 
regulating critical cellular processes.  These steps often occur on Tyrosine side chains, and to a 
lesser extent Serine/Threonine side chains, in close proximities to the molecules of interest. 
 The phosphorylation state of Tyrosine is controlled mainly by two groups of enzymes, 
Protein Tyrosine Kinases (PTKs) and Protein Tyrosine Phosphotases (PTPs).  These two work in 
a delicate balance to regulate proteins by activating/deactivating them through phosphorylation.  
Protein Tyrosine Kinases regulate proteins by transferring a phosphoryl group from ATP to the 
desired protein.  Protein Tyrosine Phosphatases work by removing the phosphoryl groups from 
the phosphorylated tyrosine resides on proteins3. 
 Among the Protein Tyrosine Phosphatases there are a total of 107 different enzymes that 
are classed into four subgroups: classical pTyr specific, dual specificity, Cdc25, and Low 
Molecular Weight PTP (LMW-PTP)1.  Low Molecular Weight Protein Tyrosine Phosphatases 
exist in two active isoforms and two inactive isoforms.  The two active isoforms are Isoform A 
and Isoform B, and the two inactive isoforms are Isoform C and SV3.  Isoform A and Isoform B 
have very slight differences.  When superimposed on top of each other, their structures look 
identical.  These PTPs all share a common active site phosphate binding P-loop (CXR(S/T)), but 
differ otherwise in sequence.  This variation determines the specificity of binding to substrates. 
 Low Molecular Weight PTPs were chosen as proteins of interest because they have 
emerged as a novel drug target based on their involvement in metabolic and tumor regulation4.  
There have been strong links between human LMW-PTPs and cancer; LMW-PTPs have been 
found to be active in the signaling pathways of growth factors5-8.  In addition, LMW-PTP mRNA 
and protein levels have been shown to be significantly increased in human breast, colon, bladder, 
and kidney tumor samples6.  Over expression of Isoform B, specifically, has been associated with 
the development of cancer and diabetes.  It has actually been discovered the two active isoforms 
play opposite roles in the early tumorigenic process, where Isoform A is anti-oncogenic and 
Isoform B is oncogenic9.  This, therefore, emphasizes the importance of identifying potent 
inhibitors of LMW-PTPs. 
Initial research found three compounds from the National Cancer Institute (NCI) Diversity 
Set I that could serve as potent inhibitors for LMW-PTP Isoform B via in silico docking methods10.  
This research group decided to expand the search and screen Diversity Set II and III, which 
composed of 1356 compounds and 1597 compounds, respectively.  For the in silico docking 
method, which was used to find compounds for the best general fit for the enzyme, all of the 
compounds were compared to an already known potent inhibitor, pyridoxal 5’-phosphate (PLP).  
This inhibitor is a competitive inhibitor for LMW-PTP with a Kis value of 7.6µM (pH 5.0).  All 
compounds that were chosen had to have comparable or better docking score to PLP.  This 
searched resulted in 47 total compounds from both sets (24 compounds from Diversity Set II and 
23 compounds from Diversity Set III), and these compounds were requested from the NCI and 
evaluated in vitro1.  Ten of the inhibitors showed strong inhibition with Kis values less than 100µM.  
Out of those inhibitors the inhibitor of interest for this study was inhibitor 156563. 
 
Figure 1. Previously discovered NCI Diversity Set II inhibitor of LMW-PTP 
Isoform B with NSC identifier number. 
 
This amino-based azo inhibitor from Diversity Set II had a Kis value of 
33.5±8.2µM.  This group aims to modify this inhibitor by shortening the 
chain length connection of a carboxylic acid group, so that the carboxylic 
acid in the para position from the nitrogen will be attached directly to the 
ring.  With this enzyme, named (E)-4-((4-carboxyphenyl)diazenyl)-3-
hydroxy-2-naphthoic acid according to IUPAC naming, this group aims 
to optimize the binding in the enzyme, maximize bond interactions, and 




Hydrochloric acid, water, p-aminobenzoic acid, sodium nitrite, sodium hydroxide, and 3-hydroxy-
2-naphthoic acid were obtained from the stockroom in Ardolf Science Center (ASC).  
 
Synthesis of (E)-4-((4-carboxyphenyl)diazenyl)-3-hydroxy-2-naphthoic acid. Hydrochloric acid 
(HCl, 1.37 mL, 1 M) and water (21.9 mL) were placed together in a 100 mL beaker. P-
aminobenzoic acid (C7H7NO2, 0.615g, 0.0045 mol) was added to this beaker and cooled over ice.  
While this was cooling, sodium nitrite (NaNO2, 0.315g, 0.0045 mol) and DI water (2.2 mL) were 
combined in a 50mL beaker. The contents of the 50mL beaker was added slowly to the 100mL 
beaker, and the solution was left to stir for 30 minutes. An alkaline solution of 3-hydroxy-2-
naphthoic acid (C11H8O3, 0.849g, 0.0045 mol) and NaOH (3 mL 2.5 M) was added to the 
mixture after the first mixture had stirred for 30 minutes. A thick, maroon paste began to form 
and the mixture was left to stir overnight. The next morning, the paste had thickened. The 
solution was acidified dropwise with dilute H2SO4 (3 mL) and boiled for five minutes on a hot 
plate at 75°C. The mixture was filtered using a Hirsch funnel. The product was then 
recrystallized in acetonitrile and dried in a vacuum oven.  The dried product was a dark maroon 
powder.  1H-NMR analysis of the product in CDCl3 displays shifts at 10.16 ppm (singlet, 1H), 8.58 ppm 
(singlet, 1H), 8.0 ppm (doublet, 2H), 7.8 ppm (doublet, 1H), 7.7 ppm (doublet, 1H), 7.5 ppm (triplet, 1H), 
and 7.36 ppm (triplet, 1H), 7.32 ppm (sing, 1H), 6.8 ppm (doublet, 2H).  1H-NMR analysis of the 
product in DMSO-d6 displays shifts at 10.2 ppm (singlet, 1H), 8.59 ppm (singlet, 2H), 8.49 ppm (doublet, 
2H), 8.43 ppm (doublet, 2H), 8.0 ppm (doublet, 2H), 7.92 ppm (doublet, 1H), 7.7 ppm (mult.), 7.5 ppm 
(triplet, 1H), and 7.31 ppm (triplet, 1H), 7.27 ppm (d. of sing, 1H), 6.78 ppm (doublet, 2H). 
In vitro kinetic assays. After synthesis of the product, kinetic studies were conducted on the 
product using pNPP, a compound used mainly in the study of kinetics of reactions catalyzed by 
phosphate enzymes.  The red color of the product presented a problem since a baseline 
fluorescence was needed.  The product was soluble in small concentrations in DMSO.  10mg of 
the compound was dissolved in 10mL of DMSO before the compound could be fully dissolved. 
 
Results & Discussion 
Spectral analysis 
From the synthesis of this new inhibitor, the 1H-NMR spectrum should essentially be a 
combination of the 1H-NMR spectra for both p-aminobenzoic acid and 3-hydroxy-2-naphthoic 
acid, with slight differences due to the absence of certain protons that were lost due to the new 
bond formed.  The figures below show the 1H-NMR spectrum for both p-aminobenzoic acid and 
3-hydroxy-2-naphthoic acid, respectively.   
 
Figure 2. 1H-NMR of p-aminobenzoic acid in DMSO-d6 with corresponding 
1H peaks labeled.  Analysis 
of spectrum displays shifts at 11.92 ppm (singlet, 1H), 7.56 ppm (doublet, 2H), 6.49 ppm (doublet, 2H), 
5.84 ppm (singlet, 3H).  
 
Figure 3. 1H-NMR of 3-hydroxy-2-naphthoic acid in CDCl3 with corresponding 
1H peaks labeled.  
Analysis of spectrum displays shifts at 10.11 ppm (singlet, 1H), 8.60 ppm (singlet, 1H), 7.8 ppm (doublet, 
1H), 7.7 ppm (doublet, 1H), 7.5 ppm (triplet, 1H), and 7.36 ppm (triplet, 1H), 7.32 ppm (sing, 1H).  
Figures 2 and 3 show the 1H-NMR spectra of p-aminobenzoic acid in DMSO-d6 and 3-
hydroxy-2-naphthoic acid in CDCl3, respectively.  The corresponding 1H peaks for has been 
labeled accordingly, so when these two compounds are brought together, the 1H spectrum for the 
product should essentially be a 1H spectrum that includes all but two of the peaks shown; peak 5 
g & i 
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of p-aminobenzoic acid and peak i of 3-hydroxy-2-naphthoic acid should disappear because the 
reaction mechanism essentially eliminates all of those protons through deprotonation or proton 
tautomerization to form the final product.  The 1H spectrum of the final product, however, 
showed almost all of these predictions with a few differences. 
 
Figure 4. 1H-NMR of product in CDCl3 with corresponding 
1H peaks labeled.  Analysis of spectrum 
displays shifts at 10.16 ppm (singlet, 1H), 8.58 ppm (singlet, 1H), 8.0 ppm (doublet, 2H), 7.8 ppm 
(doublet, 1H), 7.7 ppm (doublet, 1H), 7.5 ppm (triplet, 1H), and 7.36 ppm (triplet, 1H), 7.32 ppm (sing, 
1H), 6.8 ppm (doublet, 2H). 
A notable difference from the expected spectrum include a missing 1H peak for the 
carboxylic acid group of the p-aminobenzoic acid portion (label 1).  Another difference is the 
downfield shift of the other 1H peaks of the p-aminobenzoic (1H peaks 2 and 3).  Peak 2 shifted 
from 7.56ppm in its original structure to 8.0ppm and peak 3 shifted from 6.49ppm in its original 
structure to 6.8ppm.  The third noticeable difference is the presence of the singlet on the 3-
hydroxy-2-napthoic acid structure that was initially label i.  A possible explanation for this could 
be that some of the product may contain the intermediate preceding the final product.  That 
intermediate undergoes proton tautomerization where proton i is cleaved off to get to the final 
product structure.  The final noticeable difference is the absence of the amine peak at 5.8ppm.  
This is a keen observation because it helps to confirm that an azo bond has been formed between 
the two initial reagents.  A significant comment worth mentioning is that throughout this process, 
all 13C-NMR spectra were inconclusive because the only peaks present were solvent peaks.  
Therefore, results were based on 1H-NMR and COSY.  Efforts were carried out to run the 1H-
NMR for the product in a different solvent (DMSO-d6) in an attempt to achieve better resolution. 
Absence of 




















Figure 5. 1H-NMR of product in DMSO-d6 with corresponding 
1H peaks labeled.  Analysis of spectrum 
displays shifts at 10.2 ppm (singlet, 1H), 8.59 ppm (singlet, 2H), 8.49 ppm (doublet, 2H), 8.43 ppm 
(doublet, 2H), 8.0 ppm (doublet, 2H), 7.92 ppm (doublet, 1H), 7.7 ppm (mult.), 7.5 ppm (triplet, 1H), and 
7.31 ppm (triplet, 1H), 7.27 ppm (d. of sing, 1H), 6.78 ppm (doublet, 2H). 
Compared to the previous spectrum, a similarity that both spectra of the final product 
possess is a missing 1H peak for the carboxylic acid group of the p-aminobenzoic acid portion 
(label 1).  In addition, most of the peaks appeared at the same positions comparatively, and the 
absence of the amine peak at 5.8ppm remains constant, which again suggests that an azo bond 
has been formed between the two initial reagents.  Another similarity is the presence of the 1H 
peak on the 3-hydroxy-2-napthoic acid structure that was initially label i; however, unlike the 
previous spectrum ran in CDCl3, this spectrum displays that peak as a doublet of singlets rather 
than a singlet.  The possible explanation for this could be the same reason listed before: some of 
the product may contain the intermediate preceding the final product.  That intermediate 
undergoes proton tautomerization where proton i is cleaved off to get to the final product 
structure.   
A notable difference in this spectrum is an upfield shift of the 1H peak of the p-
aminobenzoic labeled 2, in comparison to the previous spectrum ran in CDCl3.  Peak 2 shifted 
from 8.0ppm in the spectrum ran in CDCl3 to 7.7ppm, which is closer to its original position as 
predicted by the 1H-NMR of p-aminobenzoic acid ran in DMSO-d6.  The second noticeable 
difference is the presence of new peaks at 8.43ppm and 8.0ppm, and the increase in multiplicity 
of the peak labeled 2.  A possible explanation for this could be that the additional peaks may be a 
result of instability; the final product may be breaking down.  A plausible reason for this could 
be that the product may be photosensitive and hence breaks down over time, mainly at the site of 
the azo bond.  COSY spectra were used to confirm the identity of the different protons by 
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Figure 6. COSY spectrum of product in DMSO-d6 with corresponding 
1H peaks labeled.  Analysis of 
spectrum displays connectivity between protons e & f, d & g, f & g, and 2 & 3. 
By observation of Figure 6, it is apparent that the protons on each of the previous spectrum was 
labelled correctly because connectivity has been established between select protons.  Lines 
showing connectivity were eliminated to improve the quality of the spectrum image. 
 
In vitro kinetic assays 
 To begin this analysis, fluorescence spectral analysis had to be conducted in order to 
determine the excitation wavelength.  The excitation wavelength, however, was very close to that 
of pNPP due to the very bright red color of the compound when dissolved in solution.  To 
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Figure 7.  Spectrum of both Michaelis-Menten and Lineweaver-Berk plots for the synthesized product. 
The Michaelis-Menten plot gave a plot that suggested competitive inhibition, however, this could 
be confirmed since extra date points were not taken to ensure this.  The Lineweaver-Berk plot 
also suggests competitive inhibition by displaying very similar 1/Vmax values.  The Kis value 
obtained from this study was 30.9±16.8µM.  Below is a table comparing the inhibitor 156563 to 
its derivative. 
Table 1. In vitro activity of inhibitors against LMW-PTP isoform B 
Compound (NSC #) Kis (µM) Diversity Set 







The Kis value was slightly lower compared to Inhibitor 156563; however, the margin of error 
does not allow this conclusion to be confidently made.  A possible reason for this error could be 
due to the fluorescence spectral analysis that had to be conducted in order to determine the 
excitation wavelength.  Since the excitation wavelength had to be estimated due to the product 
having a very close excitation wavelength to that of pNPP, the resulting error could not be 
avoided.  The confidence of these results, nonetheless, is not to be completely disregarded.  This 
is because PLP was tested and the Kis value of 8.6µM was comparable to the literature value. 
Conclusion 
To conclude, phosphorylation of residues in proteins is a key post-translational 
modification that serves as a common means for the control of cellular activities.  
Phosphorylation is controlled by two groups of enzymes, Protein Tyrosine Phosphatases (PTPs) 
and Protein Tyrosine Kinases (PTKs).  Protein Tyrosine Phosphatases (PTPs) are a class of 107 
enzymes that are divided into four subgroups.  One of those subgroups, Low Molecular Weight 
PTP (LMW-PTP) has two active isoforms (Isoform A and Isoform B) that differ in their p-loop 
regions.  This variation, however, determines the specificity of binding to substrates.  It has been 
discovered that over-expression of LMW-PTP Isoform B is oncogenic while Isoform A has the 
opposite effect.  This then stresses the importance of identifying potent inhibitors of LMW-PTPs, 
specifically for Isoform B. 
Inhibitor 156563, was then chosen in an effort to maximize its binding and inhibition 
capabilities by modifying its structure, mainly shortening the chain length connection of a 
carboxylic acid group.  The aim after this specific synthesis would then be to test levels of 
inhibition in vitro in hopes of obtaining lower Kis values.  The spectra for the synthesis showed a 
missing 1H peak for the carboxylic acid group of the p-aminobenzoic acid portion (label 1).  In 
addition, the absence of the amine peak at 5.8ppm suggested that an azo bond has been formed 
between the two initial reagents, while the presence of the 1H peak on the 3-hydroxy-2-napthoic 
acid structure that was initially label i still remains.  The presence of new peaks at 8.43ppm and 
8.0ppm, and the increase in multiplicity of the peak labeled 2, also suggested that the final 
product may be breaking down.  A plausible reason for this could be that the product may be 
photosensitive and hence breaks down over time, mainly at the site of the azo bond.  The 
Michaelis-Menten plot gave a plot that suggested competitive inhibition, and that was affirmed 
by the Lineweaver-Berk plot that displayed competitive inhibition by through very similar 
1/Vmax values.  The Kis value of 30.9±16.8µM was slightly lower compared to Inhibitor 156563; 
however, the margin of error does not allow this conclusion to be confidently made.  A possible 
reason for this error could be due to an error in determining the excitation wavelength of the 
product.  Since the excitation wavelength had to be estimated due to the product having a very 
close excitation wavelength to that of pNPP, the resulting error could not be avoided 
In the future, this lab group aims to conduct more tests to determine the success of the 
synthesis, as well as conduct further in vitro kinetic studies on Isoform B.  The next goal would 
then be to determine the in vitro inhibition of Isoform A as well to make sure the inhibitor is not 
a promiscuous inhibitor.  Furthermore, the group hopes to continue to synthesize inhibitors from 
database as well as modify structures of known inhibitors. 
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